HELP YOUR PATIENTS BREAK FREE WITH THE WORLD'S ONLY LONG-TERM CGM

BECOME A PROVIDER

CHANGING THE WAY
DIABETES IS MANAGED

Eversense is the only CGM system with a over 6 month subcutaneous sensor — giving patients the longest wear time ever, along with exceptional accuracy up to 6 months. Increase your patients’ satisfaction and utilization and help them break free from the burden of frequent, inconvenient and sometimes painful self-insertions.

THE EVERSENSE CGM 6-MONTH SYSTEM

Sensor

The sensor is inserted by a trained health care provider in the upper arm and continuously measures glucose for up to 6 months.

View Sensor >

Smart Transmitter

Worn over the sensor, the transmitter wirelessly sends data to user’s mobile device; removable** and rechargeable with unique on-body vibe alerts.

View Transmitter >

Mobile Application

Displays and updates real-time glucose readings every 5 minutes with intuitive graphical design to show if people are in or out of range. Remote real-time monitoring capability - up to 5 people.†

View App >

THE 6-MONTH EVERSENSE CGM SYSTEM

Long-Term Convenience

One sensor continuously for up to 6 months

Peace of Mind Accuracy

Exceptional accuracy over 6 months, including with hypoglycemia

Flexibility of Wear

Easy on, easy-off transmitter to fit your lifestyle**

Discreet Alerts

Distinct on-body vibe alerts when high or low

Gentle on Skin

Silicone-based fresh daily adhesive for comfort (can help reduce skin reactions)

Readings You Can Count On

Consistent accuracy over 6 months

SOLVING THE UNMET NEEDS OF CGM TECHNOLOGY

 

Patients with diabetes receive clinical benefit from continuous glucose monitoring when the sensor is worn more than 70% of the time.1 Limitations of CGM technology have led some to discontinue use after just the first year.2

Current CGM users cited key improvements they desire.3

  • "Longer sensor wear"
  • "Better accuracy"
  • "Better sensor adhesive"

CLINICALLY PROVEN
ACCURATE THROUGH 6 MONTHS4

Multi-site prospective pivotal clinical trial of 181 type 1 and type 2 diabetes participants.

chart.png

Only 2 sensors per year with
Eversense E3 vs 26-52 sensor changes with traditional CGMS

8.5% Overall MARD4*

Proven high user acceptability

85%

Reported improved confidence over control of their diabetes5

86%

Reported less day-to-day burden5

 

80%

were more motivated to keep up
with diabetes management5

84%

of users would choose to be inserted again5

A SIMPLE, SAFE AND STRAIGHTFORWARD PROCESS

The non-enzymatic sensor is inserted into the subcutaneous space using aseptic technique. It is a simple in-office procedure for your patient, normally twice a year.

Step One

A small ~5mm incision is made into the skin

Step Two

The sensor is placed using the custom insertion tool.

Step Three

Steri-strips™ and Tegaderm are placed over the incision, followed by the transmitter

LEARN ABOUT THE INSERTION PROCESS

"I LOVE THAT IT'S WATER-RESISTANT, SO WHEN I'M SWIMMING LAPS OR SWEATING AT THE GYM,
IT STILL WORKS.***"

- Matt, Eversense CGM User -

HEAR MORE FROM PATIENTS

EDUCATION & RESOURCES

Browse training videos, guides and more.

VIEW RESOURCES

REIMBURSEMENT GUIDE

Understand the three components of Eversense Reimbursement.

VIEW GUIDE

CONTACT US

To learn more about Eversense CGM and how to get started:

icon-call-teal.png

Give us a call at 1-844-736-7348 (844-SENSE4U)

*Eversense E3 CGM Systems include the Eversense E3 Sensor with sacrificial boronic acid (SBA) design modification.  In the PROMISE study, MARD of 8.5% was observed in the E3 Sensor with SBA, and MARD of 9.1% was observed in primary sensor without SBA design modification.
†On a compatible android or iOS device. For a full list of compatible devices, please visit https://www.ascensiadiabetes.com/eversense/compatibility/
**There is no glucose data generated when the transmitter is off
***The opinions expressed belong solely to the individual. This information provides general information only. It is not intended to be used as medical advice, diagnosis or treatment and should not replace the advice of a Health Care Provider.

1. Battelino T, Danne T, Bergenstal R, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From The International Consensus on Time in Range. Diabetes Care 2019; 42: 1595-1597. doi: 10.2337/dci19-0028.
2. Yu, S., & Varughese B, et al. (2018). Healthcare resource waste associated with Patient Nonadherence and Early discontinuation of Traditional continuous glucose monitoring in Real-world Settings: A MULTICOUNTRY ANALYSIS. Diabetes Technology & Therapeutics, 20(6), 420-427. doi: 10.1089/dia.2017.0435.
3. dQ&A Q1 2021 Panel survey.
4. Garg S. et al.. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9. DOI: 10.1089/dia.2021.0182.
5. Barnard et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology 2018, Vol. 12(3) 634–638

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.